These analyses will contribute evidence needed to inform recommendations on the use and optimal dosing of artemisinin-based combination (ACT) therapies in HIV-infected patients:

1) The Artemether-Lumefantrine / ARV PK Study Group, investigates the effect of ARV drug-drug interactions and HIV disease on artemether-lumefantrine pharmacokinetics; and

2) The ACT-ARV Safety Study Group, This is an extension of the dihydroartemisinin-piperaquine (DP) Safety Study Group, which aimed to investigate the effect of HIV disease and co-administration of widely-used ARVs on the safety of DP. The public health value of these results will be greatly enhanced by comparing these findings to the safety profile of other ACTs.

For more information and contact details of the Study Group Coordinators, please click on the links above.